Cooley-Led NeuroPace Raises $102M After Brief CFIUS Pause
Cooley-represented epilepsy treatment business NeuroPace's stock soared Thursday in its $102 million Nasdaq debut and closed up nearly 47% in an offering that came after a brief pause in the process...To view the full article, register now.
Already a subscriber? Click here to view full article